Bristol Finds Biomarkers For Improved Response To Orencia In RA
This article was originally published in The Pink Sheet Daily
Rheumatoid arthritis patients treated with Bristol’s Orencia who tested positive for two biomarkers of poor prognosis had a significantly greater response on outcomes than those who did not in a real-world data analysis presented at EULAR. The experience with TNF inhibitors was different.
Register for our free email digests: